8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Apr 15, 2026·SEC
Prelude Therapeutics Incorporated(PRLD)Earnings, Financials & Key Ratios
PRLD•NASDAQ
$4.84
$372M mkt cap·Price updated May 6, 2026
AboutPrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.Show more
- Revenue$12M+73.4%
- EBITDA-$103M+25.4%
- Net Income-$99M+21.8%
- EPS (Diluted)-1.29+23.2%
- Gross Margin85.91%-14.1%
- EBITDA Margin-847.24%+57.0%
- Operating Margin-861.33%+56.8%
- Net Margin-819.59%+54.9%
- ROE-99.45%-44.1%
- ROIC-83.35%-45.4%
- Debt/Equity0.26+89.0%
PRLD Key Insights
Prelude Therapeutics Incorporated (PRLD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Profits declining 11.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRLD Price & Volume
Prelude Therapeutics Incorporated (PRLD) stock price & volume — 10-year historical chart
Loading chart...
PRLD Growth Metrics
Prelude Therapeutics Incorporated (PRLD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM73.43%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM21.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.12%
Return on Capital
10 Years-81.43%
5 Years-62.3%
3 Years-71.62%
Last Year-87.8%
PRLD Recent Earnings
Prelude Therapeutics Incorporated (PRLD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
Mar 10, 2026EPS
$0.20
Est $0.33
+39.4%
Revenue
$6M
Est $21M
-72.7%
Q4 2025
Nov 12, 2025EPS
$0.26
Est $0.35
+25.7%
Revenue
$7M
Est $21M
-68.3%
Q3 2025
Aug 14, 2025EPS
$0.41
Est $0.45
+8.9%
Revenue
—
Q2 2025
May 6, 2025EPS
$0.42
Est $0.47
+10.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 10, 2026 | $0.20vs $0.33+39.4% | $6Mvs $21M-72.7% |
| Q4 2025 | Nov 12, 2025 | $0.26vs $0.35+25.7% | $7Mvs $21M-68.3% |
| Q3 2025 | Aug 14, 2025 | $0.41vs $0.45+8.9% | — |
| Q2 2025 | May 6, 2025 | $0.42vs $0.47+10.6% | — |
Based on last 12 quarters of dataView full earnings history →
PRLD Peer Comparison
Prelude Therapeutics Incorporated (PRLD) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 AUPH | 2.15B | 16.25 | 7.85 | 20.38% | 101.47% | 49.4% | 0.13 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% |
Compare PRLD vs Peers
Prelude Therapeutics Incorporated (PRLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRLD Income Statement
Prelude Therapeutics Incorporated (PRLD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 12.14M |
| Revenue Growth % | - | - | - | - | - | - | - | 73.43% |
| Cost of Goods Sold | 149K | 0 | 0 | 0 | 0 | 0 | 0 | 1.71M |
| COGS % of Revenue | - | - | - | - | - | - | - | 14.09% |
| Gross Profit | -149K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 7M▲ 0% | 10.43M▲ 49.0% |
| Gross Margin % | - | - | - | - | - | - | 100% | 85.91% |
| Gross Profit Growth % | - | 100% | - | - | - | - | - | 48.99% |
| Operating Expenses | 14.97M | 28.11M | 58.76M | 113.73M | 123.54M | 132.28M | 146.71M | 115M |
| OpEx % of Revenue | - | - | - | - | - | - | 2095.91% | 947.24% |
| Selling, General & Admin | 2.35M | 3.83M | 10.59M | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| SG&A % of Revenue | - | - | - | - | - | - | 410.27% | 184.56% |
| Research & Development | 12.62M | 24.28M | 48.18M | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| R&D % of Revenue | - | - | - | - | - | - | 1685.64% | 776.77% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -1.71M |
| Operating Income | -14.97M▲ 0% | -28.11M▼ 87.7% | -58.76M▼ 109.1% | -113.73M▼ 93.5% | -123.54M▼ 8.6% | -132.28M▼ 7.1% | -139.71M▼ 5.6% | -104.57M▲ 25.2% |
| Operating Margin % | - | - | - | - | - | - | -1995.91% | -861.33% |
| Operating Income Growth % | - | -87.71% | -109.05% | -93.55% | -8.62% | -7.07% | -5.62% | 25.16% |
| EBITDA | -14.83M | -27.73M | -58.22M | -112.82M | -122.22M | -131.11M | -137.94M | -102.86M |
| EBITDA Margin % | - | - | - | - | - | - | -1970.6% | -847.24% |
| EBITDA Growth % | - | -87.02% | -109.98% | -93.78% | -8.33% | -7.28% | -5.21% | 25.44% |
| D&A (Non-Cash Add-back) | 149K | 382K | 542K | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBIT | -14.97M | -28.11M | -58.76M | -113.73M | -123.54M | -132.28M | -139.71M | -104.57M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 295K | 539K | 1.83M | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Pretax Income | -14.68M▲ 0% | -27.57M▼ 87.8% | -56.93M▼ 106.5% | -111.69M▼ 96.2% | -115.44M▼ 3.4% | -121.83M▼ 5.5% | -127.17M▼ 4.4% | -99.5M▲ 21.8% |
| Pretax Margin % | - | - | - | - | - | - | -1816.76% | -819.59% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -14.68M▲ 0% | -27.57M▼ 87.8% | -56.93M▼ 106.5% | -111.69M▼ 96.2% | -115.44M▼ 3.4% | -121.83M▼ 5.5% | -127.17M▼ 4.4% | -99.5M▲ 21.8% |
| Net Margin % | - | - | - | - | - | - | -1816.76% | -819.59% |
| Net Income Growth % | - | -87.81% | -106.49% | -96.2% | -3.35% | -5.54% | -4.38% | 21.76% |
| Net Income (Continuing) | -14.68M | -27.57M | -56.93M | -111.69M | -115.44M | -121.83M | -127.17M | -99.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -9.31▲ 0% | -0.85▲ 90.9% | -1.30▼ 52.9% | -2.33▼ 79.2% | -2.27▲ 2.6% | -2.02▲ 11.0% | -1.68▲ 16.8% | -1.29▲ 23.2% |
| EPS Growth % | - | 90.87% | -52.94% | -79.23% | 2.58% | 11.01% | 16.83% | 23.21% |
| EPS (Basic) | -9.31 | -0.85 | -1.30 | -2.33 | -2.27 | -2.02 | -1.68 | -1.29 |
| Diluted Shares Outstanding | 1.58M | 32.4M | 43.71M | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Basic Shares Outstanding | 1.58M | 32.4M | 43.71M | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PRLD Balance Sheet
Prelude Therapeutics Incorporated (PRLD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.6M | 20.22M | 220.81M | 295.12M | 204.38M | 235.59M | 135.9M | 105.69M |
| Cash & Short-Term Investments | 15.6M | 18.88M | 218.31M | 291.23M | 201.73M | 232.94M | 133.61M | 103.21M |
| Cash Only | 15.6M | 18.88M | 218.31M | 31.83M | 30.61M | 25.29M | 12.47M | 35.26M |
| Short-Term Investments | 0 | 0 | 0 | 259.4M | 171.12M | 207.64M | 121.14M | 67.96M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 2.5M | 0 | 2.65M | 2.65M | 2.28M | 2.48M |
| Total Non-Current Assets | 811K | 1.65M | 2.78M | 9.98M | 16.12M | 42.08M | 39.62M | 35.62M |
| Property, Plant & Equipment | 811K | 1.65M | 2.48M | 5.64M | 6.7M | 37.74M | 35.47M | 32.28M |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.20x | 0.38x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 301K | 4.35M | 9.42M | 4.34M | 4.15M | 3.35M |
| Total Assets | 16.41M▲ 0% | 21.87M▲ 33.3% | 223.59M▲ 922.3% | 305.1M▲ 36.5% | 220.5M▼ 27.7% | 277.67M▲ 25.9% | 175.51M▼ 36.8% | 141.31M▼ 19.5% |
| Asset Turnover | - | - | - | - | - | - | 0.04x | 0.09x |
| Asset Growth % | - | 33.31% | 922.31% | 36.45% | -27.73% | 25.93% | -36.79% | -19.49% |
| Total Current Liabilities | 2.45M | 4.83M | 11.38M | 19.2M | 21.7M | 21.83M | 25.64M | 52.99M |
| Accounts Payable | 1.36M | 1.97M | 3.92M | 7.84M | 6.78M | 4.58M | 7.73M | 3.98M |
| Days Payables Outstanding | 3.34K | - | - | - | - | - | - | 849.68 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.74M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.73M |
| Other Current Liabilities | 0 | 1.63M | 420K | 5.01M | 6.21M | 6.61M | 9.79M | 12.53M |
| Current Ratio | 6.37x | 4.18x | 19.41x | 15.37x | 9.42x | 10.79x | 5.30x | 1.99x |
| Quick Ratio | 6.37x | 4.18x | 19.41x | 15.37x | 9.42x | 10.79x | 5.30x | 1.99x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 36.65M | 66.45M | 32K | 0 | 3.36M | 18.75M | 18.41M | 19.68M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.04M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 15.41M | 15.32M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 36.65M | 66.45M | 32K | 0 | 3.36M | 3.34M | 3.09M | 4.64M |
| Total Liabilities | 39.1M | 71.28M | 11.41M | 19.2M | 25.06M | 40.58M | 44.06M | 72.68M |
| Total Debt | 0 | 258K | 0 | 1.74M | 1.83M | 16.89M | 18.02M | 17.79M |
| Net Debt | -15.6M | -18.62M | -218.31M | -30.09M | -28.77M | -8.4M | 5.55M | -17.47M |
| Debt / Equity | - | - | - | 0.01x | 0.01x | 0.07x | 0.14x | 0.26x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -22.69M▲ 0% | -49.41M▼ 117.7% | 212.18M▲ 529.4% | 285.9M▲ 34.7% | 195.44M▼ 31.6% | 237.09M▲ 21.3% | 131.46M▼ 44.6% | 68.64M▼ 47.8% |
| Equity Growth % | - | -117.74% | 529.42% | 34.74% | -31.64% | 21.31% | -44.55% | -47.79% |
| Book Value per Share | -14.40 | -1.52 | 4.85 | 6.01 | 4.13 | 3.93 | 1.73 | 0.89 |
| Total Shareholders' Equity | -22.69M | -49.41M | 212.18M | 285.9M | 195.44M | 237.09M | 131.46M | 68.64M |
| Common Stock | 0 | 0 | 4K | 5K | 5K | 5K | 5K | 5K |
| Retained Earnings | -22.93M | -50.5M | -107.43M | -219.12M | -334.56M | -456.39M | -583.56M | -683.06M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -191K | 0 | -223.59M | -711K | -1.69M | 223K | 35K | 8K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRLD Cash Flow Statement
Prelude Therapeutics Incorporated (PRLD) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.95M | -25.66M | -46.18M | -83.53M | -83.73M | -107.06M | -102.89M | -56.3M |
| Operating CF Margin % | - | - | - | - | - | - | -1469.83% | -463.77% |
| Operating CF Growth % | - | -98.12% | -79.92% | -80.89% | -0.24% | -27.87% | 3.9% | 45.28% |
| Net Income | -14.68M | -27.57M | -56.93M | -111.69M | -115.44M | -121.83M | -127.17M | -99.5M |
| Depreciation & Amortization | 149K | 382K | 542K | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Stock-Based Compensation | 180K | 846K | 5.58M | 20.93M | 25.14M | 25.62M | 21.34M | 11.91M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 15K | 10K | 11K | 2.69M | 4.31M | -1.54M | -3.05M | 1.53M |
| Working Capital Changes | 1.38M | 667K | 4.62M | 3.63M | 932K | -10.48M | 4.22M | 28.41M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 721K | 546K | 1.16M | 3.9M | -347K | -2.27M | 3.31M | -3.92M |
| Cash from Investing | -529K | -780K | -621K | -263.8M | 81.69M | -34.65M | 90.19M | 53.46M |
| Capital Expenditures | -529K | -780K | -621K | -2.32M | -3.02M | -3.51M | -764K | -67K |
| CapEx % of Revenue | - | - | - | - | - | - | 10.91% | 0.55% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 17.94M | 29.73M | 246.23M | 164.9M | 815K | 136.4M | -120K | 24.82M |
| Debt Issued (Net) | 0 | -124K | -258K | 0 | 0 | 0 | -395K | -208K |
| Equity Issued (Net) | 17.94M | 29.85M | 246.4M | 161.42M | 0 | 135.73M | 329K | 25.04M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 5K | 88K | 3.47M | 815K | 664K | -54K | -17K |
| Net Change in Cash | 4.45M▲ 0% | 3.28M▼ 26.3% | 199.43M▲ 5972.8% | -182.44M▼ 191.5% | -1.22M▲ 99.3% | -5.31M▼ 334.5% | -12.82M▼ 141.2% | 21.97M▲ 271.4% |
| Free Cash Flow | -13.48M▲ 0% | -26.45M▼ 96.1% | -46.8M▼ 77.0% | -85.85M▼ 83.5% | -86.75M▼ 1.0% | -110.58M▼ 27.5% | -103.65M▲ 6.3% | -56.37M▲ 45.6% |
| FCF Margin % | - | - | - | - | - | - | -1480.74% | -464.32% |
| FCF Growth % | - | -96.14% | -76.96% | -83.46% | -1.04% | -27.47% | 6.26% | 45.62% |
| FCF per Share | -8.55 | -0.82 | -1.07 | -1.80 | -1.83 | -1.83 | -1.37 | -0.73 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.93x | 0.81x | 0.75x | 0.73x | 0.88x | 0.81x | 0.57x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRLD Key Ratios
Prelude Therapeutics Incorporated (PRLD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -69.95% | -44.85% | -47.97% | -56.34% | -69.01% | -99.45% |
| Return on Invested Capital (ROIC) | - | - | - | -68.33% | -43.86% | -50.19% | -57.31% | -83.35% |
| Gross Margin | - | - | - | - | - | - | 100% | 85.91% |
| Net Margin | - | - | - | - | - | - | -1816.76% | -819.59% |
| Debt / Equity | - | - | - | 0.01x | 0.01x | 0.07x | 0.14x | 0.26x |
| FCF Conversion | 0.88x | 0.93x | 0.81x | 0.75x | 0.73x | 0.88x | 0.81x | 0.57x |
| Revenue Growth | - | - | - | - | - | - | - | 73.43% |
PRLD SEC Filings & Documents
Prelude Therapeutics Incorporated (PRLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRLD Frequently Asked Questions
Prelude Therapeutics Incorporated (PRLD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prelude Therapeutics Incorporated (PRLD) reported $12.1M in revenue for fiscal year 2025.
Prelude Therapeutics Incorporated (PRLD) grew revenue by 73.4% over the past year. This is strong growth.
Prelude Therapeutics Incorporated (PRLD) reported a net loss of $99.5M for fiscal year 2025.
Dividend & Returns
Prelude Therapeutics Incorporated (PRLD) has a return on equity (ROE) of -99.5%. Negative ROE indicates the company is unprofitable.
Prelude Therapeutics Incorporated (PRLD) had negative free cash flow of $56.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More PRLD
Prelude Therapeutics Incorporated (PRLD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates